• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

洛拉替尼治疗罕见的伴EML4-ALK融合的肺黏液表皮样癌：1例报告并文献复习

Lorlatinib in the treatment of a rare pulmonary mucoepidermoid carcinoma with EML4-ALK fusion: a case report and literature review.

作者信息

Xu Zijun, Cong Xiaofeng, Liu Ziling

机构信息

Cancer Center, The First Hospital of Jilin University, Changchun, China.

出版信息

Front Oncol. 2024 Aug 29;14:1415254. doi: 10.3389/fonc.2024.1415254. eCollection 2024.

DOI:10.3389/fonc.2024.1415254
PMID:39267825
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11390346/
Abstract

Pulmonary mucoepidermoid carcinoma (PMEC) is a rare tumor with limited clinical data available due to its low incidence. So far, there are no universal treatment guidelines for this malignant tumor. We present here the case of a 59-year-old female never smoker who was initially referred to our hospital with cough and hemoptysis and was eventually diagnosed with PMEC. Based on further genetic testing, echinoderm microtubule-associated protein-like4-anaplastic lymphoma kinase (EML4-ALK) fusion variants E20:A20 (V2) was found. The patient was treated with lorlatinib as the first-line treatment. This case is the first to describe the effectiveness of lorlatinib in treating an advanced high-grade PMEC with EML4-ALK fusion V2 mutation patient.

摘要

肺黏液表皮样癌（PMEC）是一种罕见肿瘤，因其发病率低，可用的临床数据有限。到目前为止，对于这种恶性肿瘤尚无通用的治疗指南。我们在此介绍一例59岁从不吸烟的女性患者，该患者最初因咳嗽和咯血转诊至我院，最终被诊断为PMEC。基于进一步的基因检测，发现了棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶（EML4-ALK）融合变体E20:A20（V2）。该患者接受洛拉替尼作为一线治疗。该病例是首例描述洛拉替尼治疗晚期高级别PMEC伴EML4-ALK融合V2突变患者有效性的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d78/11390346/62e68e8cd431/fonc-14-1415254-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d78/11390346/8127c94bc780/fonc-14-1415254-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d78/11390346/1bd46b311ab5/fonc-14-1415254-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d78/11390346/62e68e8cd431/fonc-14-1415254-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d78/11390346/8127c94bc780/fonc-14-1415254-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d78/11390346/1bd46b311ab5/fonc-14-1415254-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d78/11390346/62e68e8cd431/fonc-14-1415254-g003.jpg

相似文献

1
Lorlatinib in the treatment of a rare pulmonary mucoepidermoid carcinoma with EML4-ALK fusion: a case report and literature review.洛拉替尼治疗罕见的伴EML4-ALK融合的肺黏液表皮样癌：1例报告并文献复习
Front Oncol. 2024 Aug 29;14:1415254. doi: 10.3389/fonc.2024.1415254. eCollection 2024.
2
Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.克唑替尼耐药后 EML4-ALK 融合阳性 NSCLC 转化为 SCLC 伴 V1180L 突变，对洛拉替尼治疗有效：病例报告及文献复习。
Lung Cancer. 2023 Dec;186:107415. doi: 10.1016/j.lungcan.2023.107415. Epub 2023 Oct 28.
3
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.新型人源性 EML4-ALK 融合细胞系鉴定核苷酸还原酶 RRM2 为 NSCLC 中激活的 ALK 的靶点。
Lung Cancer. 2022 Sep;171:103-114. doi: 10.1016/j.lungcan.2022.07.010. Epub 2022 Jul 25.
4
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.洛拉替尼治疗初治 ALK 阳性晚期 NSCLC 患者的疗效与 EML4::ALK 变异类型以及 ALK 是否伴有 TP53 突变有关。
J Thorac Oncol. 2023 Nov;18(11):1581-1593. doi: 10.1016/j.jtho.2023.07.023. Epub 2023 Aug 3.
5
Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.肺腺癌伴复杂 EML4-ALK 融合和 BRAF V600E 共突变对艾乐替尼有反应。
Medicine (Baltimore). 2022 Oct 7;101(40):e30913. doi: 10.1097/MD.0000000000030913.
6
miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.miR-100-5p 赋予 EML4-ALK 阳性 NSCLC 对 ALK 酪氨酸激酶抑制剂克唑替尼和洛拉替尼的耐药性。
Biochem Biophys Res Commun. 2019 Apr 2;511(2):260-265. doi: 10.1016/j.bbrc.2019.02.016. Epub 2019 Feb 18.
7
Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.获得性多重突变 ALK I1171N、L1196M 和 G1202R 介导 EML4-ALK 重排恶性胸膜间皮瘤对 lorlatinib 的耐药性：一例报告。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620935770. doi: 10.1177/1753466620935770.
8
A case report: Pathological complete response to neoadjuvant lorlatinib for Epithelioid inflammatory myofibroblastic sarcoma with EML4-ALK rearrangement.病例报告：新辅助洛拉替尼治疗伴有EML4-ALK重排的上皮样炎性肌纤维母细胞肉瘤的病理完全缓解。
Front Pharmacol. 2024 Jul 31;15:1401428. doi: 10.3389/fphar.2024.1401428. eCollection 2024.
9
Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase () rearrangements and co-existing alterations-a retrospective cohort study.阿来替尼在不同间变性淋巴瘤激酶（ALK）重排及共存改变的肺腺癌患者中的疗效——一项回顾性队列研究
Transl Lung Cancer Res. 2023 Dec 26;12(12):2505-2519. doi: 10.21037/tlcr-23-658. Epub 2023 Nov 22.
10
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.建立非小细胞肺癌获得性 lorlatinib 耐药细胞系及其介导的耐药机制。
Clin Transl Oncol. 2022 Nov;24(11):2231-2240. doi: 10.1007/s12094-022-02884-x. Epub 2022 Jul 19.

本文引用的文献

1
EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.EML4-ALK 生物学与非小细胞肺癌的药物耐药性：新发现阶段。
Mol Oncol. 2023 Jun;17(6):950-963. doi: 10.1002/1878-0261.13446. Epub 2023 May 15.
2
Lorlatinib as a treatment for ALK-positive lung cancer.洛拉替尼治疗间变性淋巴瘤激酶阳性肺癌。
Future Oncol. 2022 Aug;18(24):2745-2766. doi: 10.2217/fon-2022-0184. Epub 2022 Jul 5.
3
Mucoepidermoid Carcinoma of the Parotid Gland Presenting as a Fungating Exophytic Mass: A Surgical Challenge Rooted in Extensive Nerve Encasement.
腮腺黏液表皮样癌表现为外生性溃疡性肿物：源于广泛神经包绕的手术挑战
Cureus. 2020 Oct 16;12(10):e10990. doi: 10.7759/cureus.10990.
4
[Clinicopathologic features and epidermal growth factor receptor gene mutation of primary pulmonary mucoepidermoid carcinoma].[原发性肺黏液表皮样癌的临床病理特征及表皮生长因子受体基因突变]
Zhonghua Bing Li Xue Za Zhi. 2016 Sep 8;45(9):612-6. doi: 10.3760/cma.j.issn.0529-5807.2016.09.005.
5
Prognostic factors of primary pulmonary mucoepidermoid carcinoma: a clinical and pathological analysis of 34 cases.原发性肺黏液表皮样癌的预后因素：34例临床病理分析
Int J Clin Exp Pathol. 2014 Sep 15;7(10):6792-9. eCollection 2014.
6
Mucoepidermoid carcinoma.黏液表皮样癌
BMJ Case Rep. 2014 Aug 1;2014:bcr-2013-202776. doi: 10.1136/bcr-2013-202776.
7
Histopathologic, immunophenotypic and cytogenetic features of pulmonary mucoepidermoid carcinoma.肺黏液表皮样癌的组织病理学、免疫表型和细胞遗传学特征。
Mod Pathol. 2014 Nov;27(11):1479-88. doi: 10.1038/modpathol.2014.72. Epub 2014 Apr 18.
8
A case of pulmonary mucoepidermoid carcinoma responding to carboplatin and paclitaxel.一例肺黏液表皮样癌对卡铂和紫杉醇有反应。
Jpn J Clin Oncol. 2014 May;44(5):493-6. doi: 10.1093/jjco/hyu016. Epub 2014 Mar 11.
9
Mucoepidermoid carcinoma of the parotid gland treated by surgery and postoperative radiation therapy: clinicopathologic correlates of outcome.腮腺黏液表皮样癌经手术和术后放射治疗：结局的临床病理相关性。
Laryngoscope. 2013 Dec;123(12):3049-55. doi: 10.1002/lary.24238. Epub 2013 Aug 8.
10
Primary tracheobronchial mucoepidermoid carcinoma--a retrospective study of 32 patients.原发性气管支气管黏液表皮样癌——32 例回顾性研究。
World J Surg Oncol. 2013 Mar 9;11:62. doi: 10.1186/1477-7819-11-62.